Jacobs Levy Equity Management’s LENZ Therapeutics LENZ Stock Holding History

Jacobs Levy Equity Management’s Portfolio LENZ Stock Details LENZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.07M	Sell	117,011 -153,908	-57%	-$2.16M	﹤0.01%	693
2025 Q4	$4.33M	Buy	+270,919	New	+$7.9M	0.02%	437
2024 Q2	–	Sell	-37,176	Closed	-$830K	–	1060
2024 Q1	$830K	Buy	37,176 +10,598	+40%	+$220K	﹤0.01%	748
2023 Q4	$487K	Hold	26,578	–	–	﹤0.01%	833
2023 Q3	$461K	Hold	26,578	–	–	﹤0.01%	817
2023 Q2	$484K	Buy	+26,578	New	+$531K	﹤0.01%	828

Other funds holding LENZ

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

AWG

Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

7IH

72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return

Jacobs Levy Equity Management's LENZ Position: Q1 2026 in Review

Jacobs Levy Equity Management reduced its LENZ Therapeutics (LENZ) stake by 57% in Q1 2026, selling an estimated $2.16M and leaving 117,011 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #693.

Jacobs Levy Equity Management first reported a position in LENZ in Q2 2023 and has held it in 6 quarters since. The position peaked at $4.33M in Q4 2025. 145 funds tracked by Wall St. Rank hold LENZ as of Q1 2026.

Jacobs Levy Equity Management held 117,011 shares of LENZ Therapeutics worth $1.07M as of Q1 2026.
Jacobs Levy Equity Management sold 153,908 LENZ Therapeutics shares in Q1 2026, an estimated $2.16M.
LENZ Therapeutics made up ﹤0.01% of Jacobs Levy Equity Management's portfolio in Q1 2026, its #693 holding.
Jacobs Levy Equity Management first reported a position in LENZ Therapeutics in Q2 2023 and has held it in 6 quarters since.
Jacobs Levy Equity Management's LENZ Therapeutics position peaked at $4.33M in Q4 2025.
145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2026, filed 15 May 2026.